New molecular insights into osteosarcoma targeted therapy

被引:275
|
作者
Yang, Jilong [1 ]
Zhang, Wei [2 ]
机构
[1] Tianjin Med Univ Canc Hosp & Inst, Dept Bone & Soft Tissue Tumors, Tianjin 300060, Peoples R China
[2] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
关键词
genetic aberration; microRNA; molecular target; osteosarcoma; pathogenesis; TUMOR-GROWTH; GENE-EXPRESSION; CELL-LINES; IN-VITRO; PATHWAY; METASTASIS; OVEREXPRESSION; APOPTOSIS; PROTEIN; CANCER;
D O I
10.1097/CCO.0b013e3283622c1b
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of reviewRecent translational studies in osteosarcoma are discussed with the purpose to shed light on the new molecular therapeutic targets.Recent findingsThe genetic aberrations of vascular endothelial growth factor (VEGF), mammalian target of rapamycin, Wnt signaling pathway, the inactivation of p53, Rb, WWOX genes, and amplification of APEX1, c-myc, RECQL4, RPL8, MDM2, VEGFA might be involved in the pathogenesis of osteosarcoma. The promising therapeutic targets for osteosarcoma patients include: integrin, ezrin, statin, NOTCH/HES1, matrix metalloproteinases (MMPs), m-calpain, and Src, which are involved in tumor cell invasion and metastasis; aldolase A, fructose-bisphosphate, sulfotransferase family 3A, member 1, BCL2-associated athanogene 3, heat shock protein 70 (HSP70), B-cell lymphoma 2-interacting mediator (BIM), polo-like kinase 1, hypoxia inducible factor 1, alpha subunit, minibrain-related kinase, Bcl-xl, caspase-3, midkine, high mobility group box 1 protein (HMGB1), and Beclin1, which are involved in tumor proliferation and apoptosis; met proto-oncogene (hepatocyte growth factor receptor), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, insulin-like growth factor (IGF)-1R, fms-related tyrosine kinase 4, platelet-derived growth factor receptor, beta polypeptide, IGF-I/II, and c-kit, which are involved in tumor growth; endosialin, VEGF, thrombin, and MMPs, which are involved in tumor angiogenesis; transforming growth factor-/, parathyroid hormone-like hormone, interleukin-6, interleukin-11, receptor activator of nuclear factor-B ligand, nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1, and cathepsin, which are involved in osteoclast function; Myc, HSP90, p-Met, p-Akt, p-STAT3, and cyclin D1, which are transcriptional factors; p-GP, hydroxysteroid (17-beta) dehydrogenase 10, HMGB1, BIM, inorganic phosphate, Bcl-2, PARP, mdm2, p21, Bax, and mitogen-activated protein kinase 1, which are involved in drug sensitivity. Furthermore, microRNAs such as miR-215 are also therapeutic targets.SummaryThese translational studies in osteosarcoma have identified new molecular targets for osteosarcoma.
引用
收藏
页码:398 / 406
页数:9
相关论文
共 50 条
  • [1] New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma
    Lu, Ko-Hsiu
    Lu, Eric Wun-Hao
    Lin, Chiao-Wen
    Yang, Jia-Sin
    Yang, Shun-Fa
    PHARMACOLOGY & THERAPEUTICS, 2020, 214
  • [2] HER2-Targeted Therapy in Osteosarcoma
    Gill, Jonathan
    Hingorani, Pooja
    Roth, Michael
    Gorlick, Richard
    CURRENT ADVANCES IN OSTEOSARCOMA: CLINICAL PERSPECTIVES: PAST, PRESENT AND FUTURE, 2ND EDITION, 2020, 1257 : 55 - 66
  • [3] Advances in targeted therapy for osteosarcoma based on molecular classification
    Chen, Yingqian
    Liu, Runzhi
    Wang, Wei
    Wang, Chen
    Zhang, Ning
    Shao, Xuejing
    He, Qiaojun
    Ying, Meidan
    PHARMACOLOGICAL RESEARCH, 2021, 169
  • [4] Insights into the roles of miRNAs; miR-193 as one of small molecular silencer in osteosarcoma therapy
    Izadpanah, Sama
    Shaban, Parastoo
    Aghebati-Maleki, Ali
    Baghbani, Elham
    Baghbanzadeh, Amir
    Fotouhi, Ali
    Bakhshinejad, Babak
    Aghebati-Maleki, Leili
    Baradaran, Behzad
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 111 : 873 - 881
  • [5] Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature
    PosthumaDeBoer, J.
    Witlox, M. A.
    Kaspers, G. J. L.
    van Royen, B. J.
    CLINICAL & EXPERIMENTAL METASTASIS, 2011, 28 (05) : 493 - 503
  • [6] HA-DOPE-Modified Honokiol-Loaded Liposomes Targeted Therapy for Osteosarcoma
    Zhang, Xiangxiang
    Chen, Huaen
    Zhang, Yang
    Huang, Qijing
    Feng, Jianjia
    Xing, Haoyu
    Fu, Xiaguo
    Yan, Xiufang
    Zhang, Yingying
    Xu, Qin
    Liang, Jianming
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2022, 17 : 5137 - 5151
  • [7] Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma
    Shaikh, Atik Badshah
    Li, Fangfei
    Li, Min
    He, Bing
    He, Xiaojuan
    Chen, Guofen
    Guo, Baosheng
    Li, Defang
    Jiang, Feng
    Dang, Lei
    Zheng, Shaowei
    Liang, Chao
    Liu, Jin
    Lu, Cheng
    Liu, Biao
    Lu, Jun
    Wang, Luyao
    Lu, Aiping
    Zhang, Ge
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (04)
  • [8] Recent Insights into Therapy Resistance in Osteosarcoma
    Prudowsky, Zachary D.
    Yustein, Jason T.
    CANCERS, 2021, 13 (01) : 1 - 18
  • [9] Current Status and Prospects of Targeted Therapy for Osteosarcoma
    Hu, Zunguo
    Wen, Shuang
    Huo, Zijun
    Wang, Qing
    Zhao, Jiantao
    Wang, Zihao
    Chen, Yanchun
    Zhang, Lingyun
    Zhou, Fenghua
    Guo, Zhangyu
    Liu, Huancai
    Zhou, Shuanhu
    CELLS, 2022, 11 (21)
  • [10] Advances in Targeted Therapy for Osteosarcoma
    Zhou, Wenya
    Hao, Mengze
    Du, Xiaoling
    Chen, Kexin
    Wang, Guowen
    Yang, Jilong
    DISCOVERY MEDICINE, 2014, 17 (96) : 301 - 307